Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Allowed in Residential Care Settings for Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Families and caregivers may wonder whether residential care settings can legally administer cannabis to people with dementia. While medical cannabis is legal in the UK, its use is strictly regulated, and dementia is not an approved condition for cannabis treatment under current NHS or NICE guidelines. 

Can medical cannabis be accessed legally for women’s health?

The Legal Framework for Cannabis Use 

Cannabis-based medicinal products (CBPMs) were made legally available in the UK in 2018 under the Misuse of Drugs Regulations 2001 (UK Legislation). However, cannabis remains a controlled drug, meaning that its use must be prescribed by a specialist doctor registered with the General Medical Council (GMC) and on the Specialist Register. 

While cannabis may be prescribed for approved conditions such as severe epilepsy or MS-related spasticity, it is not approved for treating the cognitive or behavioural symptoms of dementia (NICE NG97). 

Cannabis Administration in Residential Care 

In residential care settings, cannabis is not routinely prescribed for dementia. If cannabis is considered for off-label use (e.g., to manage agitation or sleep issues), it can only be administered in compliance with strict legal and clinical protocols. This includes: 

  1. Specialist Prescription: Only specialist doctors can prescribe cannabis, even in care homes. 
  1. Controlled Drug Procedures: Cannabis must be stored and administered under strict controlled-drug regulations. This includes maintaining a controlled drugs register, securely storing the cannabis product in a locked cabinet, and recording all doses in the Medication Administration Record (MAR). 
  1. Ongoing Monitoring: Residents who are prescribed cannabis must be closely monitored for side effects, such as sedation, confusion, and balance issues.  

Ethical and Legal Considerations 

Informed consent is a fundamental requirement when using cannabis in any care setting. According to the Mental Capacity Act 2005 (UK Legislation), if a dementia patient lacks the capacity to consent, decisions about cannabis use must be made in their best interest, with family and healthcare professionals involved in the process. 

Additionally, any covert administration (giving cannabis without the patient’s knowledge or consent) is illegal unless explicitly authorised under best-interest protocols. 

Clinical Bottom Line 

  • Cannabis is not approved for dementia care under NHS or NICE guidelines. 
  • Residential care settings may only administer cannabis if prescribed by a specialist doctor for an approved condition, under strict regulatory guidelines. 
  • Ongoing monitoring and controlled-drug procedures must be followed for safety. 
  • Informed consent or best-interest decisions are required for all cannabis administration. 

Educational Context: AlleviMed 

AlleviMed provides educational resources to help care homes understand the legal and clinical frameworks for cannabis-based medicinal products. It offers guidance on how to manage cannabis prescriptions safely within residential care settings. 

Takeaway 

In residential care settings, cannabis can only be used for dementia under very specific circumstances. It must be prescribed by a specialist doctor for an approved condition, with strict monitoring and documentation in place. Until more evidence emerges and legal guidelines change, cannabis is not routinely prescribed for dementia care. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories